41.17BMarket Cap18.39P/E (TTM)
47.800High45.750Low3.08MVolume46.900Open46.950Pre Close144.82MTurnover0.36%Turnover Ratio18.39P/E (Static)865.86MShares55.00052wk High7.95P/B41.17BFloat Cap30.30052wk Low--Dividend TTM865.86MShs Float69.900Historical High--Dividend LFY4.37%Amplitude11.500Historical Low46.988Avg Price1000Lot Size--Div YieldTTM--Div Yield LFY
AKESO Stock Forum
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
Pharmaceuticals were sold off. $REMEGEN(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK)$ ...
ColumnsAnxin International - Pharmaceutical Industry Biweekly Report: The results of Chinese medicine decoction pieces combined selection landing, 2023ASCO abstract released
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...
Phase II clinical trial of AK112 combined with paclitaxel and chemotherapy in advanced non-small cell lung cancer
Objective sustained release rate (ORR) 53.8%, disease control rate (DCR) 100%, grade 3 or above treatment
The incidence of related adverse events was 13.5%. In combination with the PARP inhibitor olaparil for ovarian cancer
Phase Ib/II clinical, ORR/DCR 40.0%/86.7%. We expect it to be around 2024 on the market.
No comment yet